Sero-epidemiology of Priority Arboviruses in French Guiana (EPI-ARBO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03210363|
Recruitment Status : Active, not recruiting
First Posted : July 6, 2017
Last Update Posted : January 28, 2019
|Condition or disease||Intervention/treatment||Phase|
|Arbovirus Infections||Other: Human Biological samples||Not Applicable|
French Guiana is a 250,000 inhabitant's French overseas department located in South America, the epidemiology of arboviruses has recently evolved and marked by important outbreaks.
Dengue remains an important public health problem despite the efforts of local health authorities to mitigate the impact of epidemics and the epidemiology of dengue evolved from an endemo-epidemic to a hyper-endemic state. In late 2013, the first local transmission of chikungunya virus in the Americas was identified in Caribbean countries and territories including French Guiana. Rapidly, more than 16,000 suspected local Health authorities had reported cases. In May 2015, the Pan American Health Organization (PAHO) issued an alert regarding the first confirmed Zika virus infections in Brazil. The emergence of Zika virus in South America led to a rapid spread throughout South and Central America, reaching French Guiana in December 2015. With the increasing frequency of epidemics related to arbovirus and the resulting health, social, and economic impacts of dengue, the surveillance of arbovirus have become social, political, and public health challenges that require specific and non-available immune status information.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2697 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Sero-epidemiology of Priority Arboviruses in French Guiana|
|Actual Study Start Date :||June 9, 2017|
|Actual Primary Completion Date :||November 21, 2017|
|Estimated Study Completion Date :||June 30, 2019|
Experimental: Guiana population
Human Biological samples from Guiana population :
Two serum tubes of blood will be collected
Other: Human Biological samples
- Dengue, chikungunya, zika Antibodies detection by multiplex serologic tests [ Time Frame: 2 years ]Description of the virological status of individuals by Mutiplex detection of antibodies directed against dengue, chikungunya and zika arboviruses.
- Seroprevalence by area and age [ Time Frame: 2 years ]Estimatation of the frequency of Dengue, Chikungunya and zika infections among the general population of French Guiana by geographical area and by age class
- Dengue infections proportion [ Time Frame: 2 years ]Proportion of dengue primary and multiple infections in Guiana population.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03210363
|Institut Pasteur de la Guyane|
|Cayenne, France, 97306|
|Principal Investigator:||Claude Flamand||Institut Pasteur de la Guyane|